• Rating:
  • Manufacturer:
  • Model:
    1061
  • Available:
    In stock
  • Availability date:
    2020-07-30
  • Dosage form:
    bottle
  • In stock:
    1221 Items

$49.40
In stock
Guaranteed refund or reship if you haven't received your order
Secure and encrypted payment processing
We ship to over 40 countries including the USA, UK, Europe, Australia and Japan

DOTAVIST INSTRUCTIONS FOR USE COMPOSITION

active substance: gadotheric acid 1 ml gadotheric acid 279.32 mg (0.5 mmol), which corresponds to gadoterate meglumine 376, 92 mg excipients: meglumine, water for injection. DOSAGE FORM Solution for injection.

BASIC PHYSICAL AND CHEMICAL PROPERTIES: transparent colorless or slightly yellowish solution, practically free of mechanical impurities.

PHARMACOLOGICAL GROUP Paramagnetic contrast agents. Gadotheric acid. ATX code V08C A02. PHARMACOLOGICAL PROPERTIES Pharmacological. Gadotheric acid has paramagnetic properties that enhance image contrast in magnetic resonance imaging (MRI). Gadotheric acid has no specific pharmacodynamic activity and is biologically highly inert. Pharmacokinetics. After injection, gadotheric acid is distributed in the extracellular fluids of the body. Gadotheric acid does not bind to plasma albumin. In patients with normal renal function, the plasma half-life is approximately 90 minutes. Gadoteric acid is excreted unchanged by glomerular filtration. In renal failure, clearance is slowed down. In animals, the level of excretion of gadoteric acid into milk is low, and penetration through the placental barrier is slow. To date, there are no data on kinetics in the elderly, children, pregnant or breastfeeding women, or in patients with liver damage.

INDICATIONS It is used exclusively for diagnostic purposes if the use of magnetic resonance imaging (MRI) without contrast enhancement is impossible. Adults Contrast enhancement on MRI. MRI of the brain and spinal cord: detection of tumors of the brain, spine, surrounding tissues, prolapse of intervertebral discs, infectious diseases. MRI of the whole body, including visualization of pathology of the kidneys, heart, uterus, ovaries, organs of the chest and abdominal cavity, osteoarticular pathology. Angiography. Children (0-18 years old) Contrast enhancement with MRI. MRI of the brain and spinal cord: detection of tumors of the brain, spine, surrounding tissues, prolapse of intervertebral discs, infectious diseases. MRI of the whole body, including visualization of pathology of the kidneys, heart, uterus, ovaries, organs of the chest and abdominal cavity, osteoarticular pathology.

CONTRAINDICATIONS Hypersensitivity to gadotrevoy acid, meglumine or to any medicinal product containing gadolinium.

INTERACTION WITH OTHER DRUGS AND OTHER INTERACTIONS No interaction with other drugs has been observed. A proper study of drug interactions has not been conducted. Concomitant medications to be taken into account. Beta-blockers, vasoactive substances, ACE inhibitors, angiotensin II receptor antagonists - these drugs reduce the effectiveness of the mechanism of cardiovascular compensation in blood pressure disorders. Before the administration of gadolinium compounds, it is necessary to inform the radiologist that the patient is taking the listed drugs, and the equipment for resuscitation should be prepared in advance.

PECULIARITIES OF APPLICATION Do not use the intrathecal route of administration. Strictly follow the rules for intravenous injection, extravasation can lead to local intolerance reactions requiring conventional local treatment. Normal MRI precautions should be taken: Patients with pacemakers, ferromagnetic vascular clamps, infusion pumps, nerve stimulants, cochlear implants, or suspected intracorporeal metallic foreign bodies, especially in the eye, are contraindications for MRI. Hypersensitivity As with other contrast media containing gadolinium, hypersensitivity reactions, including life-threatening ones, may occur. Hypersensitivity reactions can be allergic (described as anaphylactic reactions if identified as serious) or Non-allergic. Reactions can be immediate (less than 60 minutes) or delayed (up to 7 days). Anaphylactic reactions occur immediately and can be fatal. Anaphylactic reactions are dose-independent, can occur even after the first dose of the drug, and are often unpredictable. Regardless of the dose administered, there is always a risk of developing hypersensitivity. Patients who have already developed a reaction upon prior administration of a contrast agent containing gadolinium have an increased risk of another reaction upon further administration of the same drug or possibly other drugs, therefore such patients are at high risk of developing allergic reactions.